Health & TechFDA approves Livsayis, a four-times-a-year shot for myasthenia gravis
Livsayis is the first siRNA drug for anti-AChR-positive generalized myasthenia gravis. In a 24-week trial, 77 percent of adults improved on daily-living scores, compared with 44 percent on placebo. It carries a meningococcal infection warning.
Verified · WebMD






















